Compare SGRP & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRP | GDTC |
|---|---|---|
| Founded | 1967 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 12.4M |
| IPO Year | 1996 | 2021 |
| Metric | SGRP | GDTC |
|---|---|---|
| Price | $0.61 | $0.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 39.6K | 6.0K |
| Earning Date | 03-31-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $136,104,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.73 |
| 52 Week High | $1.41 | $3.68 |
| Indicator | SGRP | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 45.37 | 42.31 |
| Support Level | $0.50 | $0.97 |
| Resistance Level | $0.83 | $1.06 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 63.12 | 45.62 |
SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. The company provides five principal types of services: Merchandising, Marketing and Category Management, Remodel and Retail Transformation, Assembly and Installation, Fulfilment and Distribution, and Business Analytics and Insights. It operates in two segments, namely the U.S. and Canada, with the majority of the revenues deriving from the U.S. segment.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.